Citations

Clear

6274 citation(s) found for "To, Andrew".

Whole-Transcriptome Analysis by RNA Sequencing for Genetic Diagnosis of Mendelian Skin Disorders in the Context of Consanguinity
Youssefian, Leila , Saeidian, Amir Hossein , Palizban, Fahimeh , Bagherieh, Atefeh , Abdollahimajd, Fahimeh , Sotoudeh, Soheila , Mozafari, Nikoo , Farahani, Rahele A., Zabihi, Masoud , Fortina, Paolo , Salas‐Alanís, Julio C., Vahidnezhad, Hassan , Uitto, Jouni , Mahmoudi, Hamidreza , Babashah, Sadegh , Zeinali, Sirous , South, Andrew P.

Mayo Clinic

Clinical Chemistry | March 9, 2021 | Volume: 67 | Issue: 6 | Pages: 876-888

10.1093/clinchem/hvab042 | PMID 33969388 Get It

Abstract Background Among the approximately 8000 Mendelian disorders, >1000 have cutaneous manifestations. In many of these conditions, the underlying mutated genes have been identified by DNA-based techniques which, however, can overlook certain types of mutations, such as exonic-synonymous and deep-intronic sequence variants. Whole-transcriptome sequencing by RNA sequencing (RNA-seq) can identify such mutations and provide information about their consequences. Methods We analyzed the whole transcriptome of 40 families with different types of Mendelian skin disorders with extensive genetic heterogeneity. The RNA-seq data were examined for variant detection and prioritization, pathogenicity confirmation, RNA expression profiling, and genome-wide homozygosity mapping in the case of consanguineous families. Among the families examined, RNA-seq was able to provide information complementary to DNA-based analyses for exonic and intronic sequence variants with aberrant splicing. In addition, we tested the possibility of using RNA-seq as the first-tier strategy for unbiased genome-wide mutation screening without information from DNA analysis. Results We found pathogenic mutations in 35 families (88%) with RNA-seq in combination with other next-generation sequencing methods, and we successfully prioritized variants and found the culprit genes. In addition, as a novel concept, we propose a pipeline that increases the yield of variant calling from RNA-seq by concurrent use of genome and transcriptome references in parallel. Conclusions Our results suggest that “clinical RNA-seq” could serve as a primary approach for mutation detection in inherited diseases, particularly in consanguineous families, provided that tissues and cells expressing the relevant genes are available for analysis.
Antifibrotics Modify B-Cell–Induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis
Ali, Mohamed F. , Egan, Ashley M. , Shaughnessy, Gaja F., Anderson, Dagny K., Dasari, Harika , Keulen, Virginia P. Van , Aubry, Marie‐Christine, Yi, Eunhee S. , Peikert, Tobias, Carmona, Eva M. , Carmona, Eva M , Kottom, Theodore J. , Aubry, Marie-Christine, Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | March 9, 2021 | Volume: 64 | Issue: 6 | Pages: 722-733

10.1165/rcmb.2020-0387oc | PMID 33689587 Get It

Abstract B-cell activation is increasingly linked to numerous fibrotic lung diseases, and it is well known that aggregates of lymphocytes form in the lung of many of these patients. Activation of B-cells by pattern recognition receptors (PRRs) drives the release of inflammatory cytokines, chemokines, and metalloproteases important in the pathophysiology of pulmonary fibrosis. However, the specific mechanisms of B-cell activation in patients with idiopathic pulmonary fibrosis (IPF) are poorly understood. Herein, we have demonstrated that B-cell activation by microbial antigens contributes to the inflammatory and profibrotic milieu seen in patients with IPF. B-cell stimulation by CpG and β-glucan via PRRs resulted in activation of mTOR-dependent and independent pathways. Moreover, we showed that the B-cell–secreted inflammatory milieu is specific to the inducing antigen and causes differential fibroblast migration and activation. B-cell responses to infectious agents and subsequent B-cell–mediated fibroblast activation are modifiable by antifibrotics, but each seems to exert a specific and different effect. These results suggest that, upon PRR activation by microbial antigens, B-cells can contribute to the inflammatory and fibrotic changes seen in patients with IPF, and antifibrotics are able to at least partially reverse these responses.
Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer’s Disease or Dementia with Lewy Bodies
Gupta, Harsh , Beach, Thomas G. , Mehta, Shyamal H. , Shill, Holly A. , Driver‐Dunckley, Erika , Sabbagh, Marwan N. , Belden, Christine M. , Liebsack, Carolyn, Dugger, Brittany N. , Sue, Lucia I., Siderowf, Andrew , Pontecorvo, Michael J. , Mintun, Mark A., Joshi, Abhinay D., Dugger, Brittany N , Serrano, Geidy E. , Adler, Charles H.

Mayo Clinic

Journal of Alzheimer's Disease | March 9, 2021 | Volume: 80 | Issue: 4 | Pages: 1603-1612

10.3233/jad-200323 | PMID 33720879 Get It

Background: Imaging biomarkers have the potential to distinguish between different brain pathologies based on the type of ligand used with PET. AV-45 PET (florbetapir, Amyvid™) is selective for the neuritic plaque amyloid of Alzheimer’s disease (AD), while AV-133 PET (florbenazine) is selective for VMAT2, which is a dopaminergic marker. Objective: To report the clinical, AV-133 PET, AV-45 PET, and neuropathological findings of three clinically diagnosed dementia patients who were part of the Avid Radiopharmaceuticals AV133-B03 study as well as the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND). Methods: Three subjects who had PET imaging with both AV-133 and AV-45 as well as a standardized neuropathological assessment were included. The final clinical, PET scan, and neuropathological diagnoses were compared. Results: The clinical and neuropathological diagnoses were made blinded to PET scan results. The first subject had a clinical diagnosis of dementia with Lewy bodies (DLB); AV-133 PET showed bilateral striatal dopaminergic degeneration, and AV-45 PET was positive for amyloid. The final clinicopathological diagnosis was DLB and AD. The second subject was diagnosed clinically with probable AD; AV-45 PET was positive for amyloid, while striatal AV-133 PET was normal. The final clinicopathological diagnosis was DLB and AD. The third subject had a clinical diagnosis of DLB. Her AV-45 PET was positive for amyloid and striatal AV-133 showed dopaminergic degeneration. The final clinicopathological diagnosis was multiple system atrophy and AD. Conclusion: PET imaging using AV-133 for the assessment of striatal VMAT2 density may help distinguish between AD and DLB. However, some cases of DLB with less-pronounced nigrostriatal dopaminergic neuronal loss may be missed.
Post–Liver Transplant Early Allograft Dysfunction Modifies the Effect of Pre–Liver Transplant Renal Dysfunction on Post–Liver Transplant Survival
Wadei, Hani M. , Mai, Martin L., Hodge, David O. , White, Launia J. , Croome, Kristopher P. , Taner, C. Burcin , Mao, Shennen A. , Jarmi, Tambi , Croome, Kris P , Wadei, Hani M , Keaveny, Andrew P. , Yang, Liu , Mai, Martin L.

Mayo Clinic

Liver Transplantation | March 9, 2021 | Volume: 27 | Issue: 9 | Pages: 1291-1301

10.1002/lt.26047 | PMID 33687745 Get It

Pre–liver transplantation (LT) renal dysfunction is associated with poor post‐LT survival. We studied whether early allograft dysfunction (EAD) modifies this association. Data on 2,856 primary LT recipients who received a transplant between 1998 and 2018 were retrospectively reviewed. Patients who died within the first post‐LT week or received multiorgan transplants and previous LT recipients were excluded. EAD was defined as (1) total bilirubin ≥ 10 mg/dL on postoperative day (POD) 7, (2) international normalized ratio ≥1.6 on POD 7, and/or (3) alanine aminotransferase or aspartate aminotransferase ≥2000 IU/mL in the first postoperative week. Pre‐LT renal dysfunction was defined as serum creatinine >1.5 mg/dL or on renal replacement therapy at LT. Patients were divided into 4 groups according to pre‐LT renal dysfunction and post‐LT EAD development. Recipients who had both pre‐LT renal dysfunction and post‐LT EAD had the worst unadjusted 1‐year, 3‐year, and 5‐year post‐LT patient and graft survival, whereas patients who had neither renal dysfunction nor EAD had the best survival (P < 0.001). After adjusting for multiple factors, the risk of death was significantly higher only in those with both pre‐LT renal dysfunction and post‐LT EAD (adjusted hazard ratio [aHR], 2.19; 95% confidence interval [CI], 1.58‐3.03; P < 0.001), whereas those with renal dysfunction and no EAD had a comparable risk of death to those with normal kidney function at LT (aHR, 1.12; 95% CI, 0.86‐1.45; P = 0.41). Results remained unchanged when pre‐LT renal dysfunction was redefined using different glomerular filtration rate cutoffs. Pre‐LT renal dysfunction negatively impacts post‐LT survival only in patients who develop EAD. Livers at higher risk of post‐LT EAD should be used with caution in recipients with pre‐LT renal dysfunction.
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , Al-Hawary, Mahmoud M. , Arain, Mustafa A., Chen, Yi‐Jen , Ciombor, Kristen K. , Cooper, Harry S. , Deming, Dustin A. , Farkas, Linda M., Garrido‐Laguna, Ignacio , Grem, Jean L. , Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Kirilcuk, Natalie, Krishnamurthi, Smitha , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Patel, Hitendra , Pedersen, Katrina S. , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Willett, Christopher G. , Gregory, Kristina M., Gurski, Lisa A., Hubbard, Joleen, Meyerhardt, Jeffrey A , Pedersen, Katrina , Venook, Alan P. , Cohen, Stacey A. , Gunn, Andrew, Hubbard, Joleen M. , Miller, Eric D. , Parikh, Aparna R. , Patel, Hitendra, Saltz, Leonard B. , Schneider, Charles John , Stoffel, Elena M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 5, 2021 | Volume: 19 | Issue: 3 | Pages: 329-359

10.6004/jnccn.2021.0012 | PMID 33724754 Get It

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation–positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org . Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.
Community prevalence, mechanisms and outcome of mitral or tricuspid regurgitation
Cahill, Thomas J. , Prothero, Anthony, Wilson, Jo, Kennedy, Andrew , Brubert, Jacob , Masters, Megan , Newton, James D. , Prendergast, Bernard , Prendergast, Bernard D , Myerson, Saul G , Enriquez-Sarano, Maurice , Dawkins, Sam , Enriquez‐Sarano, Maurice

Mayo Clinic

Heart | March 5, 2021 | Volume: 107 | Issue: 12 | Pages: 1003-1009

10.1136/heartjnl-2020-318482 | PMID 33674352 Get It

Objective The study aims were (1) to identify the community prevalence of moderate or greater mitral or tricuspid regurgitation (MR/TR), (2) to compare subjects identified by population screening with those with known valvular heart disease (VHD), (3) to understand the mechanisms of MR/TR and (4) to assess the rate of valve intervention and long-term outcome. Methods Adults aged ≥65 years registered at seven family medicine practices in Oxfordshire, UK were screened for inclusion (n=9504). Subjects with known VHD were identified from hospital records and those without VHD invited to undergo transthoracic echocardiography (TTE) within the Oxford Valvular Heart Disease Population Study (OxVALVE). The study population ultimately comprised 4755 subjects. The severity and aetiology of MR and TR were assessed by integrated comprehensive TTE assessment. Results The prevalence of moderate or greater MR and TR was 3.5% (95% CI 3.1 to 3.8) and 2.6% (95% CI 2.3 to 2.9), respectively. Primary MR was the most common aetiology (124/203, 61.1%). Almost half of cases were newly diagnosed by screening: MR 98/203 (48.3%), TR 69/155 (44.5%). Subjects diagnosed by screening were less symptomatic, more likely to have primary MR and had a lower incidence of aortic valve disease. Surgical intervention was undertaken in six subjects (2.4%) over a median follow-up of 64 months. Five-year survival was 79.8% in subjects with isolated MR, 84.8% in those with isolated TR, and 59.4% in those with combined MR and TR (p=0.0005). Conclusions Moderate or greater MR/TR is common, age-dependent and is underdiagnosed. Current rates of valve intervention are extremely low.
Healthcare disparities among anticoagulation therapies for severe COVID‐19 patients in the multi‐site VIRUS registry
Kirkup, Christian , Puranik, Arjun, Conrad, Ian, Gomaa, Dina , Mosier, Jarrod , Заболотских, И. Б. , Daugherty, Steven K., Bernstein, Michael, Zaren, Howard A. , Bansal, Vikas , Pickering, Brian , Badley, Andrew D. , Camazine, Maraya , Koritala, Thoyaja , O'Horo, John C, Bansal, Vikas , Soundararajan, Venky , Badley, Andrew D , Mosier, Jarrod M , Pawlowski, Colin , O’Horo, John C. , Banner‐Goodspeed, Valerie , Kashyap, Rahul , Venkatakrishnan, A J , Soundararajan, Venky

Mayo Clinic

Journal of Medical Virology | March 5, 2021 | Volume: 93 | Issue: 7 | Pages: 4303-4318

10.1002/jmv.26918 | PMID 33666246 Get It

Abstract Here we analyze hospitalized andintensive care unit coronavirus disease 2019 (COVID‐19) patient outcomes from the international VIRUS registry ( https://clinicaltrials.gov/ct2/show/NCT04323787 ). We find that COVID‐19 patients administered unfractionated heparin but not enoxaparin have a higher mortality‐rate (390 of 1012 = 39%) compared to patients administered enoxaparin but not unfractionated heparin (270 of 1939 = 14%), presenting a risk ratio of 2.79 (95% confidence interval [CI]: [2.42, 3.16]; p = 4.45e−52). This difference persists even after balancing on a number of covariates including demographics, comorbidities, admission diagnoses, and method of oxygenation, with an increased mortality rate on discharge from the hospital of 37% (268 of 733) for unfractionated heparin versus 22% (154 of 711) for enoxaparin, presenting a risk ratio of 1.69 (95% CI: [1.42, 2.00]; p = 1.5e−8). In these balanced cohorts, a number of complications occurred at an elevated rate for patients administered unfractionated heparin compared to patients administered enoxaparin, including acute kidney injury, acute cardiac injury, septic shock, and anemia. Furthermore, a higher percentage of Black/African American COVID patients (414 of 1294 [32%]) were noted to receive unfractionated heparin compared to White/Caucasian COVID patients (671 of 2644 [25%]), risk ratio 1.26 (95% CI: [1.14, 1.40]; p = 7.5e−5). After balancing upon available clinical covariates, this difference in anticoagulant use remained statistically significant (311 of 1047 [30%] for Black/African American vs. 263 of 1047 [25%] for White/Caucasian, p = .02, risk ratio 1.18; 95% CI: [1.03, 1.36]). While retrospective studies cannot suggest any causality, these findings motivate the need for follow‐up prospective research into the observed racial disparity in anticoagulant use and outcomes for severe COVID‐19 patients.
Is there value to routine oncologic surveillance after radical cystectomy? Comparative outcomes of symptomatic versus asymptomatic recurrence.
Khanna, Abhinav, Zganjar, Andrew , Shah, Paras , Tollefson, Matthew K. , Sharma, Vidit , Tarrell, Robert F., Thapa, Prabin , Pagliaro, Lance C. , Costello, Brian A. , Frank, Igor, Boorjian, Stephen A.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2021 | Volume: 39 | Issue: 6_suppl | Pages: 421-421

10.1200/jco.2021.39.6_suppl.421 Get It

421 Background: Reported rates of adherence to post-radical cystectomy (RC) surveillance guidelines in real-world practice have been as low as 9%, in part reflecting a nihilistic view held by many of the value of routine follow-up. Indeed, conflicting data exist regarding the outcomes of patients with cancer recurrence detected by scheduled surveillance versus symptom-directed evaluation. Herein, we assessed comparative outcomes of patients with symptomatic recurrence (SR) versus asymptomatic recurrence (AR) after RC. Methods: We reviewed our Institutional Registry of RC patients to identify patients with cancer recurrence following RC. Presenting symptoms in the SR cohort included pain, constitutional symptoms, gastrointestinal symptoms, and hematuria/voiding symptoms, whereas AR was defined as recurrence detected on routine surveillance in the absence of symptoms. Baseline demographic and clinical characteristics were compared between study groups using chi-square and t-test. Kaplan-Meier and Cox survival analyses were performed to compare cancer-specific survival (CSS) and overall survival (OS) between AR and SR groups. Results: Of 3822 patients who underwent RC from 1980-2018 (with a median follow-up after RC of 2.4 years (IQR 1.1,5.5), a total of 1100 were subsequently diagnosed with recurrence, including 311 (28.3%) with AR and 789 (71.7%) with SR. Median time from RC to recurrence was longer in the AR group (13.2 months) than in the SR group (10.8 months; p = 0.01). Presenting symptoms included pain (70.2%), constitutional symptoms (50.7%), gastrointestinal symptoms (23.3%), and urinary symptoms (23.3%). Median follow-up after recurrence was 2.4 years (IQR 1.1-5.5), during which time 997 patients died, including 840 who died of bladder cancer. Compared to patients with SR, patients with AR had a longer median CSS (54.5 months vs 27.3 months, p < 0.001) and OS (43.0 months vs 25.8 months, p < 0.001). On multivariable Cox proportional hazards models adjusting for demographic and clinical factors, SR was associated with a significantly increased risk of cancer-specific (hazard ratio [HR] 1.66 [95% confidence interval 1.41-1.96], p < 0.0001) and all-cause mortality (HR 1.48 [1.23-1.71], p < 0.0001). Conclusions: SR after RC is associated with worse oncologic outcomes than post-RC recurrence detected by routine surveillance. As such, continued surveillance is warranted, while further study is needed to determine the optimal follow-up regimen balancing patient and disease risks.
Urethral recurrence following radical cystectomy: Risk factors and outcomes.
Khanna, Abhinav, Zganjar, Andrew , Shah, Paras , Tollefson, Matthew K. , Karnes, R. Jeffrey , Sharma, Vidit , Tarrell, Robert F., Thapa, Prabin , Thompson, R. Houston, Frank, Igor, Boorjian, Stephen A.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2021 | Volume: 39 | Issue: 6_suppl | Pages: 416-416

10.1200/jco.2021.39.6_suppl.416 Get It

416 Background: Urethral recurrence (UR) has been reported to occur in up to 5% of patients following radical cystectomy (RC). Debate continues regarding the utility of screening for UR after RC. Moreover, oncologic outcomes of patients with UR remain incompletely described, and reports have been limited by small cohort sizes. Herein, we evaluated risk factors for UR as well as cancer-specific survival (CSS) and overall survival (OS) among patients with UR. Methods: We reviewed our institutional RC registry to identify patients with UR following RC. Logistic regression was used to assess risk factors for UR. Kaplan-Meier and Cox proportional hazard regression were used to compare outcomes in those with UR diagnosis prompted by symptoms versus those with asymptomatic UR diagnosed on surveillance cytology. Results: Overall, 2930 patients underwent RC from 1980-2018, with a median post-operative follow-up of 4.9 years (IQR 1.6-11.0), of whom 144 (4.9%) were subsequently diagnosed with UR. Prostatic urethral involvement at RC (odds ratio [OR] 5.75 [3.67-9.01], p < 0.0001) and higher pT-stage (OR 3.57 [2.07-6.14], p < 0.0001) were associated with an increased risk of UR, whereas receipt of continent urinary diversion (OR 0.34 [0.20-0.58], p < 0.0001) was associated with a decreased risk of UR. A total of 72/144 (50%) patients were diagnosed with UR based on symptoms, and 104/144 (72.2%) patients with UR underwent subsequent urethrectomy. Patients with symptomatic recurrence had higher tumor stage on urethrectomy than those with asymptomatic recurrence (≥pT2 in 13.1% vs 3.1%, p = 0.007). At a median follow-up of 2.6 years (IQR 1.0-7.1) after UR, 68 of the patients with UR died of urothelial carcinoma. Kaplan-Meier analyses suggest longer median overall and cancer-specific survival for patients with UR detected by cytology than those presenting with symptoms (p = 0.05 for both). On multivariable analyses, patients who experienced UR had significantly increased risk of cancer-specific (hazard ratio [HR] 1.93 [95% confidence interval 1.50-2.50), p < 0.0001) and all-cause mortality (HR 1.34 [1.13-1.65], p = 0.001). Conclusions: Approximately 5% of patient undergoing RC experience UR, with higher pT-stage and prostatic urethral involvement increasing the risk of UR. Asymptomatic detection of UR was associated with lower pathologic stage at urethrectomy as well as longer cancer-specific and overall survival, supporting urethral surveillance after RC.
The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression
Rhodes, Emma , Butters, Meryl A. , Morin, Ruth , Bickford, David , Tosun, Duygu , Gessert, Devon, Rosen, Howie, Aisen, Paul , Raman, Rema , Landau, Susan , Saykin, Andrew J. , Weiner, Michael W. , Nelson, Craig, Mackin, R. Scott , Initiative, on behalf of the Alzheimer’s Disease Neuroimaging, Project, the ADNI Depression, Tosun, Duygu , Saykin, Andrew J , Tosun, Duygu , Insel, Philip S. , Toga, Arthur W. , Jack, Clifford R. , Initiative, on behalf of the Alzheimer’s Disease Neuroimaging, Project, the ADNI Depression

Mayo Clinic

Journal of Alzheimer’s Disease | March 2, 2021 | Volume: 80 | Issue: 3 | Pages: 991-1002

10.3233/jad-201089 | PMID 33682706 Get It

Background: Cognitive impairment (CI) is a key feature of late life depression (LLD), but the contribution of underlying neurodegenerative pathology remains unclear. Objective: To evaluate cognitive dysfunction in LLD relative to a sample of nondepressed (ND) older adults with matched levels of memory impairment and amyloid-β (Aβ) burden. Methods: Participants included 120 LLD and 240 ND older adults matched on age, education, sex, Mini-Mental State Exam, mild cognitive impairment diagnosis, and PET Aβ burden. Results: LLD showed higher rates of impairment relative to ND with 54.6% of the LLD sample demonstrating impairment in at least one cognitive domain compared to 42.9% of controls ( H = 7.13, p = 0.008). LLD had poorer performance and higher rates of impairment on Rey Auditory Verbal Learning Test learning and memory compared to controls. In the overall sample, Aβ positivity was associated with worse performance on Logical Memory I ( p = 0.044), Logical Memory II ( p = 0.011), and Trail Making Test –B ( p = 0.032), and APOE ɛ4 genotype was associated with worse performance on Logical Memory I ( p = 0.022); these relationships did not differ between LLD and ND. Conclusion: LLD showed higher rates of CI driven by focal deficits in verbal learning and memory. Alzheimer’s disease (AD) biomarkers were associated with worse performance on timed set-shifting and story learning and memory, and these relationships were not impacted by depression status. These findings suggest that AD may account for a portion of previously reported multi-domain CI in LLD and highlight the potential for AD to confound studies of cognition in LLD.